在神经退行性疾病中蛋白相分离和聚合的病理参与
International journal of molecular sciences
|September 28, 2024
概括
神经退行性疾病涉及蛋白质错误折叠和聚合,通常与异常的细胞相分离有关. 本综述探讨了针对蛋白质聚合的治疗策略,以对抗这些衰弱的疾病.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 生物化学 生物化学
- 分子医学是分子医学.
背景情况:
- 神经退行性疾病会导致人类严重的残疾和生活质量的降低.
- 这些疾病具有共同的致病机制,包括蛋白质功能障碍,结构扭曲和聚合.
- 细胞相分离,形成生物分子凝聚物,调节重要的神经元过程.
研究的目的:
- 审查常见神经退行性疾病 (阿尔茨海默病,帕金森病,亨廷顿病) 的病理原因.
- 讨论关键的粉原蛋白的调节,重点关注异常相位分离和聚合.
- 通过干预蛋白质聚合来引入神经退行性疾病的治疗策略.
主要方法:
- 关于神经退行性疾病病理学的文献综述.
- 分析蛋白相分离和聚合机制.
- 探索针对蛋白质聚合的治疗干预措施.
主要成果:
- 异常相位分离与神经元细胞内的蛋白质聚合有关.
- 关键的amyloidogenic蛋白质是神经退行性疾病的病原体的核心.
- 干预蛋白质聚合提供了潜在的治疗途径.
结论:
- 由于异常相位分离而导致的蛋白质聚合是神经退行性疾病的常见标志.
- 了解这些机制对于开发有效治疗方法至关重要.
- 针对蛋白质聚合提供了一种有希望的策略来改善神经退行性疾病.
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451


